Pirfenidone in unclassifiable ILD (uILD): subgroup analysis of patients with/without a surgical lung biopsy (SLB)

V. Cottin (Lyon, France), T. Corte (Camperdown, New South Wales, Australia), M. Kreuter (Heidelberg, Germany), M. Molina-Molina (Barcelona, Spain), J. Axmann (Basel, Switzerland), F. Gilberg (Basel, Switzerland), K. Kirchgaessler (Basel, Switzerland), T. Maher (London, United Kingdom)

Source: Virtual Congress 2020 – What is hot in idiopathic pulmonary fibrosis?
Session: What is hot in idiopathic pulmonary fibrosis?
Session type: E-poster session
Number: 1802

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
V. Cottin (Lyon, France), T. Corte (Camperdown, New South Wales, Australia), M. Kreuter (Heidelberg, Germany), M. Molina-Molina (Barcelona, Spain), J. Axmann (Basel, Switzerland), F. Gilberg (Basel, Switzerland), K. Kirchgaessler (Basel, Switzerland), T. Maher (London, United Kingdom). Pirfenidone in unclassifiable ILD (uILD): subgroup analysis of patients with/without a surgical lung biopsy (SLB). 1802

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: